Welcome to What Can I Do With This Major?

WhatCanIDoWithThisMajor-Small-WP2Welcome to What Can I Do With This Major? Whether you are exploring multiple majors or searching for information about your chosen field, this site will help you connect majors to careers. Learn about the typical career areas and the types of employers that hire people with each major, as well as strategies to make you a more marketable candidate. Continue your research on majors and careers through the websites provided.








View All General Majors
Connect majors to careers
  View Specialized UAB Majors
Connect majors to careers
This section under construction
  How To Use This Resource
Learn about resource features
  FAQ's
Answers to common questions







UAB News

  • Landefeld named to U.S. Preventive Services Task Force
    UAB’s Landefeld named to government panel that helps determine recommendations on preventive health measures.

    C. Seth Landefeld, M.D., professor and chair of the Department of Medicine at the University of Alabama at Birmingham, has been appointed to theU.S. Preventive Services Task Force. The task force is an independent, volunteer panel composed of experts from many health-related fields, including internal medicine, pediatrics, behavioral health, obstetrics/gynecology, and nursing. Each is appointed by the director of the Agency for Healthcare Research and Quality, a part of the U.S. Department of Health and Human Services.

    Each year, the task force examines the evidence base for preventive health services — such as screenings, counseling services and preventive medications — and delivers an annual report to Congress with recommendations about whether specific clinical preventive practices help or harm the health of Americans. While its recommendations have sometimes been controversial, specifically related to mammograms for women under 50 and prostate cancer screening, the task force has had a positive impact on the role of prevention in routine doctor visits over the past 20 years.

    “We are proud to congratulate Seth on this prestigious new appointment,” said Selwyn M. Vickers, M.D., senior vice president for Medicine and dean of the UAB School of Medicine. “We are confident that his experience, skill and leadership will serve the task force well.”

    Landefeld is internationally known for his work in geriatrics, general internal medicine and health care research, with the emphasis of his work aiming to personalize health care for the elderly and to improve their outcomes. He is a thought leader on the safe delivery of medicines and care delivery models that improve geriatric outcomes.

  • Landmark Type 2 diabetes study continues — volunteers still needed
    Research volunteers are needed for a UAB study to determine which combinations of Type 2 diabetes drugs work best for different groups of people.

    Volunteers with Type 2 diabetes are still needed for a continuing national study of the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating Type 2 diabetes.

    The University of Alabama at Birmingham is one of 50 institutions across the nation participating in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study, or GRADE study. GRADE is sponsored by the National Institutes of Health with a goal of enrolling 5,000 patients nationwide.

    “The GRADE study is the first comparative effectiveness study which will look directly at the four major treatments for diabetes, compare them, and try to determine which one or ones are the best for treating Type 2 diabetes,” said Andrea L. Cherrington, M.D., associate professor of preventive medicine and co-primary investigator at UAB. “At present, there is little consensus on which combinations of the current diabetes drugs in conjunction with metformin will best serve different patient populations.”

    Metformin is widely accepted as the first medication that should be used to treat Type 2 diabetes; however, most patients eventually require an additional medication to manage the disease. The results of GRADE will help doctors guide the management of individuals with Type 2 diabetes in the future and might provide more immediate benefits now to those who participate.

    Phil Ferguson has been enrolled for more than a year. He knew his blood sugar levels had been rising over time, but he did not fully grasp the need to take control of his diabetes until he became involved in the study.

    “The best part of this study has been the people conducting it,” Ferguson said. “They are informative and compassionate and really help you understand how diabetes affects you. I’m in a much better place now for having joined the GRADE study, and I’ll miss it when it wraps up in a few years.”

    People with Type 2 diabetes may be eligible to join the GRADE study if they:

    • Have had Type 2 diabetes for less than 10 years
    • Are over 30 years old
    • Are American Indian and over 20 years old
    • Take only metformin (Glucophage®) for their diabetes
    • Are willing to take a second diabetes medication
    • Are willing to make four office visits per year for the next four to six years

    Participants in the GRADE study will receive:

    • Close follow-up from an expert diabetes care team at no cost
    • Diabetes medications and supplies at no cost
    • Diabetes care visits and lab tests at no cost
    • Diabetes education at no cost

    The GRADE study is looking to enroll a cross section of patients with Type 2 diabetes of any age, gender and ethnicity. The study will follow its participants for seven years and will provide free medications and diabetes care. Contact Dana Golson at 205-996-4015 or ccnrn@uab.edu for more information on enrolling in the study.

    “It is estimated that nearly one in three children, and one in two minority children, born after the year 2000 will develop Type 2 diabetes,” said W. Timothy Garvey, M.D., professor and chair of the Department of Nutrition Sciences, director of the UAB Diabetes Research Center, and co-primary investigator at UAB. “Type 2 diabetes progresses gradually, and this study will help us understand how different combinations of medicines affect the disease and the people who are taking those medications over time.”

    Type 2 diabetes is an epidemic that threatens to become the century’s major public health problem and poses enormous human and economic challenges worldwide. Nearly 26 million Americans are affected by diabetes, and 79 million have pre-diabetes.

    GRADE (ClinicalTrials.gov number: NCT01794143) is supported under NIH grant U01DK098246. Additional support in the form of donation of supplies comes from the National Diabetes Education Program, Sanofi-Aventis, Bristol-Myers Squibb, Novo Nordisk, Merck, BD Medical and Roche Diagnostics.

  • TAVR procedure saves Selma’s first black police chief
    Selma’s first black police chief now has new opportunities ahead thanks to a new procedure from UAB cardiologists.

    Earnest Tate is no stranger to adversity or history. When he was named the first black police chief of Selma in the late 1990s, he had to lead and unify a police force that had been heavily scrutinized during the civil rights era.

    “My goal was to make it the best police department in the state of Alabama, and I did that,” Tate said.

    Nearly 20 years later, Tate is now retired and works on his family farm in the city where he made history. But a minor heart attack that led to heart failure threatened his ability to work the land he loves so dearly.

    “I tried to not show sickness; but since my wife was a nurse, she still saw it,” Tate said. “It made a big impact on my whole family. I never got scared because I never had time to get scared.”

    Tate recalled that it was hard to breathe while standing up. He says it would take him a long time to walk from the bedroom to the kitchen.

    After consulting with his primary care physician in Selma, Tate was sent to UAB for a consultation. It was there that he met James Davies, M.D., and Oluseun Alli, M.D., and learned he had a condition called aortic stenosis.

    Aortic stenosis occurs when the heart’s aortic valve narrows, preventing the valve from opening fully.

    Mark F. Sasse, M.D., an associate professor of interventional cardiology, says Tate’s heart pumping function was significantly reduced compared to normal.

    Tate’s heart pumping function was significantly reduced, but thanks to transcatheter aortic valve replacement (TAVR) Tate can now get back to what he loves doing most — working on his farm."“The pumping function of Mr. Tate’s heart was fairly reduced, so he was at a higher risk than our normal transcatheter patients,” Sasse said. “The percentage of blood being pumped out was nearly 30 percent less than in people with normal pumping function.”

    The structural heart team of Davies, Alli and Sasse determined that Tate was a prime candidate for transcatheter aortic valve replacement.

    Sasse says transcatheter aortic valve replacement, or TAVR, provides easier recovery compared to open-heart surgery as patients typically do not stay in intensive care as long.

    In the TAVR procedure, a replacement valve is placed inside a catheter. The catheter is then threaded through blood vessels in the leg or through the chest of the patient. The valve is then positioned into the old valve while the heart is still beating. The heart is able to pump blood through the replacement valve normally.

    After the TAVR device was successfully placed, Tate said he felt physically better soon after the procedure was complete. Sasse is happy to see that his patient is doing well and ready to get back to a normal life.

    “We took a person who was very debilitated and gave him back his life,” Sasse said. “He couldn’t sleep at night. Now he can sleep. People who can’t do daily activities are able to do those things now. That’s the real benefit of this procedure.”

    After visiting with Sasse for a one-month checkup, Tate is now feeling better and is able to do the things he wants to do without feeling tired.

    “I can rest better at night,” Tate said. “I used to be too tired to eat. My appetite came back. I used to have to ride in a wheelchair, but I don’t have to ride in a wheelchair anymore.”

    UAB was the first hospital in the state of Alabama to perform the TAVR procedure, in 2012. More than 300 total cases have been completed since then.

    UAB was the first hospital in the state of Alabama to perform the TAVR procedure, in 2012. More than 300 total cases have been completed since then. Sasse says his staff averages four or five per week.

    “With people who had been considered for open-heart surgery in the past, we’ve noticed certain subgroups, typically the elderly, don’t do well,” Sasse said. “All these patients were offered high-risk surgeries or nothing at all. TAVR gave them another option.”

    The sky is the limit for people with heart failure, according to Sasse. UAB is already in its third iteration of the valve with the Sapien-3 valve.

    “The engineering keeps getting better each time,” he said. “The companies are still working on making them better. The future is bright for treating a bigger patient population.”

    That is good news for patients like Tate. Now 80 years old, Tate is back happily calling his cows and tending to his farm, and feels he has plenty ahead of him.

    “It was a relief to go home,” Tate said. “It took me several months to get sick, and I know it is going to take several months to get well. I believe now I can live to get 100 years old. It’s what I feel.”

More Items

UAB Career & Professional Development Twitter